Cellular immunotherapy for viral infection after HSC transplantation.
about
Immune Reconstitution after Allogeneic Hematopoietic Stem Cell TransplantationDifferentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapyAdoptive immunotherapy with antigen-specific T cells during extracorporeal membrane oxygenation (ECMO) for adenovirus-related respiratory failure in a child given haploidentical stem cell transplantation.Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAXControlling cytomegalovirus: helping the immune system take the leadHuman Cytomegalovirus (HCMV) - Revised.Global transcriptional analysis delineates the differential inflammatory response interleukin-15 elicits from cultured human T cellsAdoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationJacaric acid inhibits the growth of murine macrophage-like leukemia PU5-1.8 cells by inducing cell cycle arrest and apoptosisConditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7T cell receptor αβ diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection.Adenovirus infection after allogeneic stem cell transplantation.Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantationAge-related appearance of a CMV-specific high-avidity CD8+ T cell clonotype which does not occur in young adults.T cell therapy in allogeneic stem cell transplantation.T cells for viral infections after allogeneic hematopoietic stem cell transplantIL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection.Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificitiesPhotochemical approaches to T-cell activation.Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.Virus-specific T-cell therapy in solid organ transplantation.Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.Human immunity against EBV-lessons from the clinic.Granzyme M targets host cell hnRNP K that is essential for human cytomegalovirus replication.Immunotherapy for transplantation-associated viral infections.Characterization of the human herpesvirus 6 U69 gene product and identification of its nuclear localization signal.High Throughput Screening of Valganciclovir in Acidic Microenvironments of Polyester Thin Films.Mechanism of tumor remission by cytomegalovirus in a murine lymphoma model: evidence for involvement of virally induced cellular interleukin-15.A registry of HLA-typed donors for production of virus-specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune-compromised patients.Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.Single-cell T-cell receptor-β analysis of HLA-A*2402-restricted CMV- pp65-specific cytotoxic T-cells in allogeneic hematopoietic SCT.Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65.Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus.Association between γ marker, human leucocyte antigens and killer immunoglobulin-like receptors and the natural course of human cytomegalovirus infection: a pilot study performed in a Sicilian population.Design and use of conditional MHC class I ligands.Specific CD8⁺ T cells recognize human herpesvirus 6B.
P2860
Q28072627-227BFE43-B5CE-4A83-964C-5B36DF59D59EQ30479628-460B3E34-B67E-482F-8A64-31367E1E39BCQ33289956-ADB24423-B340-48E9-BC7A-7EEB33913DE2Q33410361-0DA03B85-A2EA-4754-910F-87C0862BC44AQ33634455-0867A90B-5538-4FD2-9A35-0A20DE8DD05FQ33744024-0C49A8B5-721A-4954-9423-EA03E58E5F09Q33820695-AD67FAED-739D-48C2-A74A-89DEE6C58734Q34625453-C2AA0D0D-CBDB-4B79-8A1C-60D0406212B0Q35758126-AE4AF090-8A37-452B-94FD-07A4715217E1Q35849338-CC8EF494-801C-46FF-AD46-C8156E5941ADQ36104904-0726C5D9-86C4-421D-9DBD-4AB93F0C282AQ36499204-CE84A3B8-304B-4602-A72B-49911BA5673CQ36672239-101F4D8E-FA46-4D9C-8EF5-9A7D07D6D40EQ36746433-10E73920-C4D0-4817-817A-CBFA42FAF8F7Q36962653-34B2AD45-5548-424F-89E1-2957A9576F2BQ36999534-949FEA8E-BCA8-4EAB-8BC1-F33AF06B2500Q37045973-BE49FCDE-76AC-40D1-952D-1DA042592A24Q37058107-31CB88F8-0919-4E43-9DB9-9EF21D774B20Q37068471-66060FF7-133A-4B53-B519-EA8A8FB716A6Q37319382-47A7E4B4-15B8-4879-B3DA-13BC4EC371DAQ37734571-B9741258-70BB-49DA-9B8B-EEDC4AC37CF7Q37980749-4227E865-6E19-4B9D-8527-DC76259D5CA6Q38568902-F3EF6728-A07B-4708-9845-41271071F9D7Q38802522-D55549A8-2754-4DA0-BA99-64C7C92530EDQ39097082-47E9FCF3-CE91-4031-80E4-0892C1E07C24Q39253178-A2F54624-D31B-4C05-9ECD-144C0722E230Q39382670-302EF692-65BA-4DEC-A922-79CFBA62A001Q40051825-A3AE5FFE-5D62-4378-B38A-9C9F33B5BB45Q40992924-AD1BC82C-0127-45C1-B5FB-4CEC9483B560Q41387613-DC1257BC-72CF-4330-9EDE-3E79073F3D50Q42205114-3C3C4F29-D940-424E-8584-58E6C3E02B15Q42221268-7B6599A8-0203-4E24-B43A-3363DB6B3EAFQ42277578-D3844E29-90FE-4674-9D01-0C9926B5FDC4Q43238571-C865902E-8EA4-46CB-80CA-D6E1AA977A1BQ44245356-BB332C3E-FB3E-4240-BE1D-35FE75D71123Q45415157-62075DD0-9DA9-4061-8874-CA2B2867D6ADQ47446877-5F5D13DC-6D2A-440B-83FD-7F6B92929D32Q47601337-C835F9F4-E3F7-41E7-870D-27C88872EBC2Q53637625-6CD38156-5822-4EEC-86D2-45C29FF746F1Q54296983-F1570EFD-4B7B-4C98-B7CD-0A238A8DE721
P2860
Cellular immunotherapy for viral infection after HSC transplantation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cellular immunotherapy for viral infection after HSC transplantation.
@ast
Cellular immunotherapy for viral infection after HSC transplantation.
@en
type
label
Cellular immunotherapy for viral infection after HSC transplantation.
@ast
Cellular immunotherapy for viral infection after HSC transplantation.
@en
prefLabel
Cellular immunotherapy for viral infection after HSC transplantation.
@ast
Cellular immunotherapy for viral infection after HSC transplantation.
@en
P2860
P356
P1476
Cellular immunotherapy for viral infection after HSC transplantation.
@en
P2093
Alan Rickinson
P2860
P356
10.1038/NRI1526
P577
2005-01-01T00:00:00Z